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a  b  s  t  r  a  c  t
Perampanel  is  a selective,  noncompetitive  AMPA  receptor  antagonist  with  demonstrated  efﬁcacy  and
tolerability  in  partial  seizures  in patients  aged  ≥12  years  in  Phase  III studies.  Post-hoc  analysis  of
these  studies  was  conducted  to determine  the  efﬁcacy  and  tolerability  of perampanel  based on  the
number  of concomitant  antiepileptic  drugs  (AEDs)  at  baseline,  as well  as  to  examine  which  base-
line  characteristics,  if any, were  predictors  of efﬁcacy.  Efﬁcacy  parameters  were  based  on the  number
of  baseline  AEDs,  and  logistic  regression  analyses  were  used  to  evaluate  the  association  of  demo-
graphic  and  baseline  clinical  factors  with  probability  of  ≥50%  reduction  in seizure  frequency.  Patients
on  1 AED  at baseline  were  signiﬁcantly  more  likely  to have  reduced  seizure  frequency  (P <  0.02)  and
improved  50%  responder  rate  (P <  0.02)  than  patients  on  3  AEDs  at  baseline.  Secondarily  generalized
seizures  at baseline,  unknown  etiology,  and  use of  concomitant  non-inducer  AEDs  were  also  estab-
lished  as  positive  predictors  of efﬁcacy  (50% responder  rate;  P  <  0.01).  Patients  with  more  AEDs  at
baseline  were  associated  with  greater  use  of inducers  (P < 0.01),  which  may  result  in  decreased  exposure
of perampanel  in these  patients  and  lower  efﬁcacy.  Patients  with  1 AED  at baseline  had  a  signiﬁ-
cantly shorter  time  since  diagnosis  compared  with  patients  in the  3  (P  <  0.01)  AEDs  group,  as  well  as
a  lower  median  seizure  frequency  at baseline  compared  to  patients  on 3 AEDs  (P  < 0.05),  suggesting
that  the reduced  efﬁcacy  of  perampanel  with  3 AEDs  may  also  be  associated  with the  greater  sever-
ity  of seizures  in  the  patient  groups.  The  incidence  of adverse  events  in  perampanel-treated  patients
was  similar  regardless  of the number  of  AEDs  at baseline.  Greater  efﬁcacy  is  predicted  for  patients
receiving  fewer  concomitant  AEDs  when  starting  perampanel,  as well  as  for  those  receiving  con-
comitant  treatment  with  AEDs  that  are  not  CYP3A4  enzyme-inducers,  compared  to  patients  treated
with  multiple  concomitant  AEDs.  The  results  of this  study  provide  additional  information  for  clini-
cians  considering  adding  perampanel  to  their  patients’  treatment  regimen  earlier  rather  than  later,
and  offer  evidence  regarding  the  potential  for  increased  efﬁcacy  with  a decreased  medication  bur-
den.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: AED, antiepileptic drug; ANCOVA, analysis of covariance; BMI,
ody mass index; CI, conﬁdence interval; CNS, central nervous system; SAE, serious
dverse event; TEAE, treatment-emergent adverse event.
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1. Introduction
Perampanel, a ﬁrst-in-class antiepileptic drug (AED), is
approved for adjunctive treatment of partial seizures with or
without secondarily generalized seizures and for primary gener-
alized tonic-clonic seizures in patients aged 12 years or older with
epilepsy (FYCOMPA US Prescribing Information, 2015; Rektor,
2013). Perampanel is a selective, noncompetitive AMPA receptor
antagonist and has demonstrated efﬁcacy and tolerability in
patients aged ≥12 years with partial seizures in 3 multicenter,
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ouble-blind, randomized, placebo-controlled, Phase III stud-
es, with patients taking stable doses of up to 3 approved AEDs
French et al., 2012, 2013; Krauss et al., 2012). Although perampanel
as not been shown to meaningfully affect the plasma concentra-
ions of concomitant AEDs, data from population pharmacokinetic
nalyses in clinical studies indicate that co-administration of the
YP3A4 enzyme-inducing AEDs carbamazepine, oxcarbazepine,
nd phenytoin affects the metabolism of perampanel and results
n lower plasma concentrations (Brodie et al., 2013; Fuseau et al.,
011; Gidal et al., 2013; Krauss et al., 2012).
There are over 20 different AEDs available for treatment of
pilepsy, a common neurological disease (Fisher et al., 2014;
rench, 2007; Loscher and Schmidt, 2011) that affects more than
5 million people worldwide (Institute of Medicine of the National
cademies, 2012). Approximately half of these treatments have
een developed within the last 15 years (French, 2007), and the
ewer generation AEDs offer more favorable pharmacokinetics,
etter tolerability, and improved drug interaction proﬁles than
hose developed previously (Bialer, 2012; Verrotti et al., 2011). This
ange of options allows physicians to tailor treatment for each indi-
idual patient (Bialer, 2012; Franco et al., 2013). However, despite
hese advances in antiepileptic treatments, patient outcomes still
emain poor (Loscher and Schmidt, 2011; French, 2007). Approx-
mately 30% of patients with epilepsy are still resistant to drug
reatment (Brodie, 2010; French, 2007; Perucca et al., 2007), as
eﬁned by a failure of at least 2 adequate trials of AEDs (Kwan
t al., 2010). In addition to the uncontrolled seizures, there is a
igher incidence of physical, mental, and social adverse outcomes
n patients who fail to achieve seizure freedom with the ﬁrst pre-
cribed AED (Perucca et al., 2011).
The inability to identify which patients will respond to treat-
ent (have fewer seizures or become seizure free) can lead to a
trial-and-error” approach in prescribing drugs and other thera-
ies that may  be less than optimal (FDA, 2013). Because there is
 wide variation in the effectiveness and safety proﬁle of current
EDs, it is important for physicians to consider developing per-
onalized AED therapy for patients with epilepsy and distinguish
hose patients most likely to beneﬁt from a given treatment (FDA,
013), especially since many patients are drug-resistant. This “pre-
ision medicine” targets both AED efﬁcacy and safety to ensure
hat patients get the right treatment. In order to optimize AED
herapy and provide precision medicine to patients with epilepsy,
t is important to consider the genetics and medical history of
he individual, as well as the concomitant AEDs they are receiv-
ng (Depondt, 2008; Robinson, 2012; Walker et al., 2014). Rational
olytherapy of AED combinations with differing mechanisms of
ction can be an option for drug-resistant patients to help con-
rol seizures and achieve seizure freedom with minimal impact on
uality of life (French and Faught, 2009; St Louis, 2009). The con-
ept of rational polytherapy suggests that the combination of drugs
ith different mechanisms of action is more likely to have additive
ntiepileptic effects and produce seizure freedom (Barker-Haliski
t al., 2014; Brodie and Sills, 2011; French and Faught, 2009; St
ouis, 2009). This report aims to explore patient baseline charac-
eristics to determine potential predictors of perampanel’s efﬁcacy.
peciﬁcally, this study examines the efﬁcacy and tolerability of
erampanel based on the number of concomitant AEDs at base-
ine in a post hoc analysis of the 3 Phase III perampanel clinical
tudies.
. Methods.1. Study design and patients
The 3 Phase III studies (study 304, NCT00699972; study 305,
CT00699582; and study 306, NCT00700310) were conductedarch 119 (2016) 34–40 35
between April 2008 and January 2011 in more than 40 countries.
All studies were conducted in accordance with the Helsinki Dec-
laration, European Medicines Agency requirements, and the US
Code of Federal Regulations, as appropriate. Study protocols,
amendments, and informed consents were reviewed by national
regulatory authorities in each country and by independent ethics
committees or institutional review boards for each site. Prior
to participation, all patients provided written informed consent
(French et al., 2012, 2013; Krauss et al., 2012; Steinhoff et al.,
2013).
These studies, described in detail elsewhere, included a 6-
week baseline period, a 19-week double-blind treatment phase
(a 6-week titration period followed by a 13-week maintenance
period), and a 4-week follow-up period or continuation in the
open-label extension study. In all 3 studies, patients entered the
pre-randomization phase and were assessed for baseline seizure
frequency and eligibility for the 19-week, double-blind treatment
phase. Eligible patients included those aged ≥12 years diagnosed
with partial seizures with or without secondary generalization in
accordance with the 1981 International League Against Epilepsy
Classiﬁcation of Epileptic Seizures (International League Against
Epilepsy, 1981), and who  had experienced ≥2 AED failures and
had ≥5 partial seizures during baseline. Patients were required to
have been on a stable dose of any concomitant benzodiazepines
(French et al., 2013). Patients had to have been on stable doses of 1
to 3 approved AEDs for at least 21 days prior to pre-randomization
(French et al., 2012, 2013; Krauss et al., 2012). Of the 3 AEDs,
patients were allowed one CYP3A4 enzyme-inducing AED, deﬁned
as carbamazepine, phenytoin, phenobarbital, or primidone at the
time of enrollment. Later analysis of the plasma concentration
of perampanel and pharmacokinetic modeling of the pooled data
from the Phase III studies showed that carbamazepine, oxcar-
bazepine, and phenytoin were the clinically important inducers of
perampanel metabolism. In this current analysis, carbamazepine,
oxcarbazepine, and phenytoin are deﬁned as perampanel CYP3A4
inducers (Brodie et al., 2013; Gidal et al., 2013; Hussein et al., 2011,
2012).
Following the 6-week baseline period, patients were random-
ized to placebo or perampanel doses of 2, 4, 8 or 12/mg day (French
et al., 2012, 2013; Krauss et al., 2012). During the 6-week titration
period, perampanel doses were increased by 2 mg/day/week until
the randomized dose or intolerability was  reached. Dose reduc-
tion was permitted at the investigators’ discretion for patients
experiencing intolerable adverse events, but more than one 2-
mg  down-titration at a time was discouraged. If tolerability later
improved, up-titration was  allowed in these patients. During the
13-week maintenance period, patients continued on the dose
achieved during titration and continued to receive their established
concomitant AEDs without modiﬁcation. Those who  discontinued
treatment or who did not enter the extension study had a follow-
up visit 4 weeks after the end of therapy (French et al., 2012, 2013;
Krauss et al., 2012).
2.2. Measurement of efﬁcacy
Efﬁcacy was determined based on the pooled population of
patients from the three Phase III studies and on the number of base-
line concomitant AEDs taken by patients. Patients recorded seizure
frequency and type in daily diaries. Efﬁcacy endpoints included
median percent decrease in total seizure frequency per 28 days
of treatment during the double-blind period relative to the pre-
randomization phase baseline, 50% responder rate (deﬁned as the
percentage of patients who  experienced a ≥50% reduction from
baseline in seizure frequency per 28 days of treatment during the
maintenance period with last observation carried forward), and
achievement of seizure-free status.
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.3. Tolerability
Tolerability was assessed based on number of baseline AEDs and
ncluded incidence rates of treatment-emergent adverse events
TEAEs), treatment-related TEAEs, treatment-emergent serious
dverse events (SAEs), and TEAEs leading to study withdrawal.
.4. Statistical analysis
The distribution of etiology in patients with different numbers
f baseline AEDs was compared using Cochran–Mantel–Haenszel
tatistics. Time since diagnosis of epilepsy in the three different
ED groups was compared using a least squares regression model.
he baseline seizure rate in these three AED groups was compared
sing a least squares regression model based on ranks. All the com-
arisons were adjusted for treatment group.
To assess the association between efﬁcacy and the number of
aseline AEDs, the three efﬁcacy measures (i.e., median percent
ecrease in seizure frequency, 50% responder rate, and seizure-
ree status) were reported separately for each AED group. In order
o assess the impact of number of AEDs at baseline on seizure
requency efﬁcacy endpoints, an analysis of covariance on the rank-
ransformed data (rank ANCOVA) model was used to pair-wise
ompare AED groups (1 AED vs 2 AEDs, 1 AED vs 3 AEDs, and 2
EDs vs 3 AEDs). First, the baseline seizure frequency per 28 days
nd the percentage change per 28 days during treatment were
ank-transformed separately. A rank ANCOVA was then conducted
ith treatment, AED groups and the ranked baseline seizure fre-
uency per 28 days as covariates. A P value ≤0.05 was  considered
tatistically signiﬁcant.
A Cochran–Mantel–Haenszel test adjusted by treatment was
sed to compare the proportion of seizure-free status among the 3
ED groups.
For the analyses on factors predictive of efﬁcacy, logistic regres-
ion analyses were used to evaluate the association between
emographic and baseline clinical factors with 50% responder rate.
ecause the 50% responder rate is most clinically useful for physi-
ians, it was selected as the efﬁcacy outcome measure for the
ogistic regression analyses. Separate logistic regression modeling
as conducted on each baseline variable [age, gender, race, ethnic-
ty, weight, height, body mass index (BMI), time since diagnosis,
tiology, epileptogenic region, seizure type, number of AEDs at
aseline, and non-inducer vs inducer concomitant AEDs (inducers
able 1
atient demographics and baseline characteristics.
No. of concomitant AEDs Placebo 
N 1 AED 60 
2  AEDs 217 
3  AEDs 164 
Age,  median (years) 1 AED 37 
2  AEDs 34 
3  AEDs 31 
Female sex, n (%) 1 AED 40 (66.7) 
2  AEDs 105 (48.4) 
3  AEDs 76 (46.3) 
Seizure type: complex partial, n (%) 1 AED 47 (78.3) 
2  AEDs 190 (87.6) 
3  AEDs 138 (84.1) 
Seizure type: secondarily generalized, n (%) 1 AED 44 (73.3) 
2  AEDs 153 (70.5) 
3  AEDs 121 (73.8) 
Time  since diagnosis, mean (years) 1 AED 19.8 
2  AEDs 20.3 
3 AEDs 21.6 
ED = antiepileptic drug.
P < 0.05 for 1 vs 2 AEDs and P < 0.01 for 1 vs 3 AEDs.arch 119 (2016) 34–40
included carbamazepine, oxcarbazepine, or phenytoin)], control-
ling for treatment group, region, and baseline seizure rate. Factors
in these separate models with a P value <0.05 were included in a
ﬁnal multivariate logistic regression model.
3. Results
3.1. Patient demographics and baseline characteristics
Based on the pooled analysis of the 3 Phase III studies, 1478
patients were included in the efﬁcacy analysis and 1480 patients
were included in the tolerability analyses. At baseline, 206 (13.9%),
749 (50.7%), and 523 (35.4%) patients were on 1, 2, or 3 AEDs,
respectively, and were included in this analysis (Table 1). Age,
sex, and seizure type (complex partial or secondarily generalized
seizures) were not different between placebo and the perampanel
treatment groups (Table 1).
Controlling for the treatment group, etiology was not signif-
icantly different across baseline AED groups (P > 0.05) and for
most patients, etiology was unknown [n = 104 (50.5%), 1 AED;
n = 376 (50.2%), 2 AEDs; n = 236 (45.1%), 3 AEDs]. The etiologies
of structural brain anomalies/malformations, other causes, head
injury/cranial trauma and central nervous system (CNS) infections
were also reported in patients (>5% of patients for each etiology)
and were similar in patients regardless of the number of AEDs at
baseline.
Controlling for the treatment group, a longer time since diag-
nosis was  associated with a greater number of AEDs at baseline
(Table 1). For the total population (perampanel and placebo
groups), the time since diagnosis was  signiﬁcantly shorter with 1
AED (18.9 years) compared to either 2 or 3 AEDs (21.1 years and
21.9 years, respectively; P < 0.05 for 1 vs 2 AEDs and P < 0.01 for 1
vs 3 AEDs).
Carbamazepine, lamotrigine, levetiracetam, oxcarbazepine,
topiramate, and valproic acid were the most common co-
administered AEDs at baseline [≥10% of patients in the total
population (perampanel and placebo groups)] in all Phase III stud-
ies. As shown in Table 2, use of the CYP3A4 enzyme-inducing
AEDs carbamazepine, oxcarbazepine, or phenytoin was increas-
ingly higher with more AEDs at baseline (P < 0.01).
The median rate of seizures at baseline for the total popula-
tion was  signiﬁcantly higher in patients from the 3-AEDs group
Perampanel Total
2 mg 4 mg 8 mg 12 mg
30 19 69 28 206
80 88 220 144 749
70 65 142 82 523
34 36 35 30 36
31 31.5 36 34.5 34
33.5 32 34 37 33
20 (66.7) 11 (57.9) 35 (50.7) 16 (57.1) 122 (59.2)
44 (55.0) 44 (50.0) 114 (51.8) 69 (47.9) 376 (50.2)
31 (44.3) 29 (44.6) 75 (52.8) 50 (61.0) 261 (49.9)
23 (76.7) 15 (78.9) 52 (75.4) 24 (85.7) 161 (78.2)
66 (82.5) 74 (84.1) 194 (88.2) 132 (91.7) 656 (87.6)
64 (91.4) 58 (89.2) 122 (85.9) 65 (79.3) 447 (85.5)
19 (63.3) 13 (68.4) 38 (55.1) 23 (82.1) 137 (66.5)
51 (63.8) 61 (69.3) 164 (74.5) 103 (71.5) 532 (71.0)
45 (64.3) 45 (69.2) 96 (67.6) 51 (62.2) 358 (68.5)
13.2 16.8 19.7 22.2 18.9
20.1 19.6 22.3 21.7 21.1*
21.1 20.8 22.2 23.8 21.9*
T. Glauser et al. / Epilepsy Research 119 (2016) 34–40 37
Table  2
Patients on inducers vs non-inducers by number of baseline AEDs.
Number of concomitant AEDs Inducer* (Yes/No) Placebo Perampanel Total
2 mg  4 mg  8 mg 12 mg
1 AED, N 60 30 19 69 28 206
2  AEDs, N 217 80 88 220 144 749
3  AEDs, N 164 70 65 142 82 523
1  AED, n (%) No 33 (55.0) 19 (63.3) 14 (73.7) 34 (49.3) 13 (46.4) 113 (54.9)
Yes  27 (45.0) 11 (36.7) 5 (26.3) 35 (50.7) 15 (53.6) 93 (45.1)
2  AEDs, n (%) No 87 (40.1) 28 (35.0) 45 (51.1) 97 (44.1) 49 (34.0) 306 (40.9)
Yes  130 (59.9) 52 (65.0) 43 (48.9) 123 (55.9) 95 (66.0) 443 (59.1)†
3 AEDs, n (%) No 67 (40.9) 28 (40.0) 20 (30.8) 50 (35.2) 30 (36.6) 195 (37.3)
Yes  97 (59.1) 42 (60.0) 45 (69.2) 92 (64.8) 52 (63.4) 328 (62.7)†
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sED = antiepileptic drug.
* Inducers deﬁned as carbamazepine, oxcarbazepine, and phenytoin.
† Use of inducers was  increasingly higher with more AEDs (P < 0.01).
ompared with patients in the 1- or 2-AED groups (14.0 vs 9.7 and
0.8, respectively; P < 0.05).
.2. Efﬁcacy
.2.1. Percent decrease in seizure frequency
The median percent decrease in seizure frequency over 28 days
uring the double-blind phase relative to baseline was greater for
atients taking 1 AED at baseline compared to patients receiving 3
EDs (P < 0.02). A signiﬁcant difference was not observed between
atients taking 1 vs 2 AEDs (P = 0.06) and 2 vs 3 AEDs (P = 0.28) at
aseline. As shown in Fig. 1A, median percent decrease in seizure
requency relative to baseline was greater for patients taking 1
ED at baseline compared to 3 AEDs in all perampanel treatment
roups. For patients receiving 2 mg  of perampanel, the median per-
ent decrease in seizure frequency was greater for those taking 1
ED at baseline (20.6%) compared to the respective placebo group
12.5%), whereas patients taking 2 or 3 AEDs at baseline had results
imilar to the respective groups receiving placebo. Median percent
ecrease in seizure frequency for the placebo-treated patients was
imilar among the three AED groups (Fig. 1A).
.2.2. 50% responder rate
Patients taking 1 AED at baseline had a signiﬁcantly higher
0% responder rate compared to those taking 3 AEDs at baseline
P < 0.02). The 50% responder rate was higher in patients receiving
 mg  and 12 mg  compared to placebo, irrespective of the number
f AEDs at baseline (Fig. 1B).
.2.3. Seizure-free status
For all perampanel- and placebo-treated patients who com-
leted the double-blind study, the highest percentages of patients
chieving seizure-free status during the maintenance phase were
mong those taking 1 AED at baseline, except for the 2 mg  peram-
anel group, in which no one with only 1 concomitant AED achieved
eizure-free status. Overall, patients receiving 4 mg,  8 mg,  and
2 mg  of perampanel had higher percentages achieving seizure-
ree status (ranging from 2.5% to 12.5% of patients) compared to
atients receiving placebo (ranging from 0.7% to 2.0%) and 2 mg
erampanel (ranging from 0% to 2.9%), regardless of number of
aseline AEDs (Fig. 1C). No statistically signiﬁcant difference among
he three AEDs groups was observed for the proportion of patients
ith seizure-free status (P > 0.2). This may  be due to the over-
ll small number of patients completing the study and achieving
eizure-free status (Fig. 1C).3.3. Logistic regression analysis data
To evaluate the association of demographic and baseline clin-
ical factors with the probability of ≥50% reduction in seizure
frequency, logistic regression analyses were conducted. Overall,
4 variables were identiﬁed as baseline predictors for improved
efﬁcacy (Table 3). Fewer AEDs at baseline was  a predictor of
perampanel efﬁcacy in that patients on 1 AED at baseline were sig-
niﬁcantly more likely to have improved efﬁcacy (50% responder
rate) than patients on 3 AEDs (P < 0.02).
Patients with secondarily generalized seizures at baseline were
associated with improved efﬁcacy compared to those without sec-
ondarily generalized seizures (P < 0.01). Patients with unknown
etiology at baseline were more likely to be responders than those
with CNS infection etiology (P < 0.01). Additionally, patients using
non-enzyme-inducing AEDs at baseline were more likely to be
responders compared to those taking CYP3A4 enzyme-inducing
AEDs carbamazepine, oxcarbazepine, or phenytoin (P < 0.01).
3.4. Tolerability
Incidence of any TEAEs was  similar regardless of the number
of AEDs at baseline in the total perampanel population (77.4%,
76.7%, and 77.1% for 1, 2, and 3 AEDs, respectively). A similar result
was found in the placebo group (61.7%, 64.7%, and 70.7% for 1, 2,
and 3 AEDs, respectively). As reported in previous publications on
the three individual Phase III studies (French et al., 2012, 2013;
Krauss et al., 2012), the most common TEAEs included dizziness,
somnolence, headache, fatigue, and irritability, which were found
in all AED groups. The TEAEs of fall and upper respiratory tract
infection were observed at a rate of ≥5% only in total perampanel-
treated patients on 3 AEDs at baseline (6.1% and 5.0% respectively),
and at a lower rate in placebo-treated groups (3.7% for each). For
treatment-related TEAEs, treatment-emergent SAEs, or TEAEs lead-
ing to perampanel withdrawal, there was no notable difference
across baseline AED groups in the total perampanel group. Patients
treated with perampanel 8 mg  and 12 mg  had a higher incidence
of treatment-related TEAEs compared to placebo, regardless of the
number of AEDs at baseline. No deaths occurred in any treatment
group.
4. Discussion
Precision medicine aims to offer treatment for epilepsy by clas-
sifying patients into subsets with a common biological basis of the
disease, such as genetics or medical history (Robinson, 2012). This
individualized treatment aims at determining which patients will
respond best to an AED treatment, including perampanel, with few
38 T. Glauser et al. / Epilepsy Research 119 (2016) 34–40
Fig. 1. (A) Median percent decrease in seizure frequency, (B) 50% responder rates, and (C) seizure-free status by randomized dose and number of baseline AEDs. a During
the  double-blind phase. b During the maintenance phase (last observation carried forward). c n, patients who  completed the maintenance phase with seizure-free status;
percentages are based on completer set. AED = antiepileptic drug.
Table 3
Factors predictive of efﬁcacy (50% responder rate) based on logistic regression analyses.
Predictive factor* Odds ratio 95% CI Probability (P value)
Etiology
CNS infection vs unknown 0.521 0.326–0.833 0.006
Seizure  type 0.654 0.500–0.855 0.002
Without secondarily generalized seizure vs secondarily generalized seizure
Number of AEDs at baseline
1 vs 3 AEDs 1.552 1.074–2.243 0.019
2  vs 3 AEDs 1.272 0.975–1.659 0.077
Presence of inducer AED†
Inducer vs non-inducer AEDs 0.642 0.505–0.818 0.0003
C
ptoge
a
I
a
a
t
tI = conﬁdence interval; CNS = central nervous system.
* Age, gender, race, ethnicity, weight, height, BMI, time since diagnosis, and epile
† Inducers deﬁned as carbamazepine, oxcarbazepine, and phenytoin.
ssociated adverse events. This post-hoc analysis of the three Phase
II clinical studies examined the efﬁcacy and tolerability of per-
mpanel based on the number of concomitant AEDs at baseline
nd other predictors of efﬁcacy. The results of this study indicate
hat although perampanel improved seizure control, adjunctive
reatment with perampanel is associated with greater efﬁcacynic region were not signiﬁcant factors predictive of efﬁcacy (50% responder rate).
when patients are taking fewer concomitant AEDs at baseline.
Other predictors of efﬁcacy were presence of secondarily gener-
alized seizures, unknown etiology at baseline, and non-inducer
concomitant AED use. Furthermore, there were no differences in
perampanel tolerability outcomes based on the number of con-
comitant AEDs.
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Although monotherapy is recommended for the treatment of
pilepsy, a mechanism-of-action-based AED polytherapy can be an
ption for drug-resistant patients to help control seizures (St Louis,
009). Indeed, the patients enrolled in the perampanel Phase III
linical trials had already experienced at least 2 AED treatment fail-
res and were on a stable dose of 1 to 3 AEDs (French et al., 2012,
013; Krauss et al., 2012). The reduced efﬁcacy of perampanel in
atients taking 3 AEDs compared to 1 AED may  be associated with
he greater severity of seizures in the patient groups. For exam-
le, patients with 3 AEDs at baseline had a signiﬁcantly longer time
ince diagnosis (21.9 years) as well as a higher median seizure fre-
uency per 28 days at baseline (14.0) compared with patients in
he 1 AED group (18.9 years and 9.7 per 28 days, respectively).
revious research has shown that higher seizure frequency can
ndicate drug-resistant epilepsy (Kwan and Brodie, 2000). Patients
ith drug-resistant epilepsy often try a number of different AEDs
ithout gaining adequate seizure control and are therefore less
ikely to respond to subsequent treatment (Brodie, 2010; Kwan and
rodie, 2000; Luciano and Shorvon, 2007).
The reduced efﬁcacy of perampanel in patients with 3 concomi-
ant AEDs at baseline may  also be explained by their association
ith more prevalent use of the CYP3A4 enzyme-inducing con-
omitant AEDs carbamazepine, oxcarbazepine, and phenytoin.
erampanel is extensively metabolized through primary oxida-
ion, which is mediated predominantly by CYP3A4 and CYP3A5
Rogawski and Hanada, 2013). An analysis of Phase I pharma-
okinetic drug interaction studies showed a 3-fold increase in the
learance of perampanel in the presence of the enzyme-inducing
ED carbamazepine. Additionally, a Phase II pharmacokinet-
cs/pharmacodynamics study with perampanel showed that, over
 period of 20 weeks, exposure to perampanel was 2-fold lower in
atients co-administered AEDs that were strong CYP450 enzyme
nducers than in patients not receiving inducers (Fuseau et al.,
011). Data from the controlled Phase III studies were analyzed in
 population pharmacokinetic model that showed that clearance of
erampanel was signiﬁcantly increased by 2- to 3-fold in the pres-
nce of the CYP3A4 inducers carbamazepine, oxcarbazepine, and
henytoin, resulting in lower exposure to perampanel (Brodie et al.,
013; Gidal et al., 2013). These data indicate that perampanel efﬁ-
acy may  be lowered as a result of increased clearance when added
o a treatment regimen containing carbamazepine, oxcarbazepine,
nd phenytoin. Consequently, the dose of perampanel may  need to
e monitored and adjusted when administered concomitantly with
hese treatments (FYCOMPA US Prescribing Information, 2015).
The tolerability of perampanel was not notably affected by the
umber of AEDs at baseline. Indeed, the rates of any TEAEs, regard-
ess of number of concomitant AEDs at baseline, was  similar to
hose reported in the Phase III studies (French et al., 2012, 2013;
rauss et al., 2012). Falls and upper respiratory tract infection were
eported only in the patient group on 3 AEDs at baseline for both
erampanel- and placebo-treated patients. This ﬁnding of falls is
upported by a study by Petty and colleagues, which demonstrated
hat both AED polytherapy (>1 AED) and longer duration of AED
se were independent predictors of increased sway (impaired bal-
nce performance); however, the exact number of AEDs used was
ot speciﬁed in the study (Petty et al., 2010). Overall, the incidence
f TEAEs, treatment-related TEAEs, treatment-emergent SAEs, and
EAEs leading to perampanel withdrawal was similar across base-
ine AED groups.
. ConclusionsPatients receiving fewer concomitant AEDs when starting per-
mpanel, or those receiving concomitant treatment with AEDs that
re not CYP3A4 enzyme-inducers, show an improved responsearch 119 (2016) 34–40 39
with perampanel compared to those patients treated with mul-
tiple AEDs. These data provide important information for clinicians
when considering adding perampanel to a patient’s treatment ﬂow
and offers evidence on the potential for increased efﬁcacy with
decreased medication burden. Understanding drug interactions
and the patient proﬁle is important for the treatment management
of epilepsy in order to control seizures and avoid treatment-related
adverse events (St Louis, 2009). Perampanel dosing should be based
on clinical response and tolerability (FYCOMPA US Prescribing
Information, 2015) in order to provide adequate, individualized
seizure control.
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